Thursday, July 11, 2013
A group of researchers from California and New York has
identified a small molecule with activity against currently intractable
nonreplicating stages and drug-resistant strains of Mycobacterium tuberculosis.1
The compound, which works by blocking a cell wall biosynthesis enzyme and a
cofactor biosynthesis enzyme, could be combined with existing tuberculosis
drugs to help shorten treatment duration and prevent or eliminate the emergence
of resistant bacteria.
L. SciBX 6(26);
Published online July 11, 2013
1. Wang, F. et al.
Proc. Natl. Acad. Sci. USA; published online June 17, 2013;
Contact: Peter G. Schultz, The Scripps Research Institute, La Jolla,
Contact: William R. Jacobs Jr., Albert Einstein College of Medicine of
Yeshiva University, Bronx, N.Y.
COMPANIES AND INSTITUTIONS
Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y.
California Institute for Biomedical Research, La Jolla, Calif.
Comenius University in Bratislava, Bratislava, Slovakia
Global Alliance for TB Drug Development, New York, N.Y.
The Scripps Research Institute, La Jolla, Calif.
Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland
Texas A&M Health Science Center College of Medicine, Bryan, Texas
University of Birmingham, Birmingham, U.K.
University of Illinois at Chicago, Chicago, Ill.